HER2-Positive Breast Cancer

Updated findings from a randomized trial yielded new insights into the optimal duration of adjuvant trastuzumab for women with HER2-positive breast cancer.

Tremendous progress has been made in the treatment landscape for HER2-positive breast cancer that has significantly altered and improved the outlook for this patient population.

An analysis of global online conversations among health care professionals on social media in April revealed tremendous enthusiasm about FDA approval of a treatment for adults with advanced HER2-positive solid tumors.

SAN ANTONIO — The addition of atezolizumab to chemotherapy, trastuzumab and pertuzumab did not significantly increase pathologic complete response rates among women with HER2-positive breast cancer.

The addition of tucatinib to ado-trastuzumab emtansine significantly improved PFS among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, according to study findings.

CHICAGO — One-year of adjuvant trastuzumab remains the standard-of-care treatment duration for most patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.

Adjuvant paclitaxel and trastuzumab continued to appear effective after 10 years of follow up among patients with small node-negative, HER2-positive breast cancer, according to data presented at San Antonio Breast Cancer Symposium.

In this video, Sara Hurvitz, MD, discussed her presentation at 39th Miami Breast Cancer Conference.on strategies and tactics clinicians can use to de-escalate side effects for patients being treated for HER2-positive breast cancer.

Healio spoke with Amy Tiersten, MD, professor of medicine with Mount Sinai Hospital, about the treatment landscape in HER2-positive breast cancer.

The FDA granted priority review to fam-trastuzumab deruxtecan-nxki for treatment of certain patients with advanced breast cancer.